EyePoint, Inc. (EYPT)Healthcare | Biotechnology | Watertown, United States | NasdaqGM
2.99 USD
-0.08
(-2.606%) ⇩
(Oct. 14, 2026, 11:50 a.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:38 a.m. EDT
EyePoint is a distressed biotech play with deteriorating fundamentals and a collapsing market narrative. The company is reporting negative revenue growth of nearly 90%, burning significant cash, and posting negative operating margins. While analysts maintain a 'Buy' rating with a lofty $26 target price, this ignores the reality of a shrinking business and a fortress-like balance sheet that is currently being eroded by losses. The options market confirms this pessimism, with traders stacking heavy put positions at strikes far above the current price, betting on continued decline. There is no dividend to provide income, and the lack of price history prevents any assessment of long-term resilience. This is a speculative trap where the 'value' thesis fails because the core product pipeline is underperforming in Phase 3 trials. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.699874 |
| MSTL | 0.701020 |
| AutoETS | 0.701498 |
| AutoTheta | 0.717018 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 21% |
| H-stat | 209.60 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.042 |
| Excess Kurtosis | -1.46 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 13.441 |
| Revenue per Share | 0.034 |
| Market Cap | 257,774,288 |
| Forward P/E | -1.08 |
| Beta | 1.68 |
| Previous Name | EyePoint Pharmaceuticals, Inc. |
| Website | https://eyepoint.bio |
As of Oct. 10, 2026, 6:38 a.m. EDT: Speculators are positioning heavily for downside protection, with massive open interest in out-of-the-money puts (strikes 7.5, 10.0, 12.5, 15.0) relative to calls. The put/call ratio is skewed significantly toward selling, indicating a consensus expectation of further price weakness rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7382779 |
| Address1 | 480 Pleasant Street |
| Address2 | Suite C-400 |
| All Time High | 485.6 |
| All Time Low | 2.19 |
| Ask | 24.0 |
| Ask Size | 3 |
| Audit Risk | 10 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 2,676,930 |
| Average Daily Volume3 Month | 4,000,389 |
| Average Volume | 4,000,389 |
| Average Volume10Days | 2,676,930 |
| Beta | 1.683 |
| Bid | 9.0 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | 1.958 |
| City | Watertown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.99 |
| Current Ratio | 4.502 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 3.055 |
| Day Low | 2.945 |
| Debt To Equity | 13.441 |
| Display Name | EyePoint |
| Dividend Date | 1,607,472,000 |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,778,070,600 |
| Earnings Call Timestamp Start | 1,778,070,600 |
| Earnings Timestamp | 1,785,933,000 |
| Earnings Timestamp End | 1,793,795,400 |
| Earnings Timestamp Start | 1,793,795,400 |
| Ebitda | -314,376,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.339 |
| Enterprise To Revenue | 38.223 |
| Enterprise Value | 106,566,264 |
| Eps Current Year | -3.6431 |
| Eps Forward | -2.77861 |
| Eps Trailing Twelve Months | -3.75 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.7582 |
| Fifty Day Average Change | -2.7682002 |
| Fifty Day Average Change Percent | -0.48074052 |
| Fifty Two Week Change Percent | -73.82779 |
| Fifty Two Week High | 19.11 |
| Fifty Two Week High Change | -16.12 |
| Fifty Two Week High Change Percent | -0.84353745 |
| Fifty Two Week Low | 2.945 |
| Fifty Two Week Low Change | 0.045000076 |
| Fifty Two Week Low Change Percent | 0.015280162 |
| Fifty Two Week Range | 2.945 - 19.11 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,106,836,200,000 |
| Float Shares | 60,673,516 |
| Forward Eps | -2.77861 |
| Forward P E | -1.0760776 |
| Free Cashflow | -155,010,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 214 |
| Fullday Change | -0.07999992 |
| Fullday Change Percent | -2.6058607 |
| Fullday Price | 2.99 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -257,472,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03525 |
| Held Percent Institutions | 1.17045 |
| Implied Shares Outstanding | 86,212,138 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,607,472,000 |
| Last Split Factor | 1:10 |
| Long Business Summary | EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts. |
| Long Name | EyePoint, Inc. |
| Market | us_market |
| Market Cap | 257,774,288 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_4481199 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-14 |
| Net Income To Common | -306,643,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 320,709,153 |
| Number Of Analyst Opinions | 11 |
| Open | 3.04 |
| Operating Cashflow | -267,298,000 |
| Operating Margins | -192.07101 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 617 926 5000 |
| Prev Name | EyePoint Pharmaceuticals, Inc. |
| Previous Close | 3.07 |
| Price Eps Current Year | -0.8207296 |
| Price Hint | 4 |
| Price To Book | 1.5270685 |
| Price To Sales Trailing12 Months | 92.458496 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.305 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | -0.07999992 |
| Regular Market Change Percent | -2.6058607 |
| Regular Market Day High | 3.055 |
| Regular Market Day Low | 2.945 |
| Regular Market Day Range | 2.945 - 3.055 |
| Regular Market Open | 3.04 |
| Regular Market Previous Close | 3.07 |
| Regular Market Price | 2.99 |
| Regular Market Time | 1,791,993,010 |
| Regular Market Volume | 1,036,203 |
| Return On Assets | -0.74851996 |
| Return On Equity | -1.4870399 |
| Revenue Growth | -0.905 |
| Revenue Per Share | 0.034 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 86,212,138 |
| Shares Percent Shares Out | 0.24110001 |
| Shares Short | 20,788,240 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 18,110,761 |
| Short Name | EyePoint, Inc. |
| Short Percent Of Float | 0.2538 |
| Short Ratio | 5.85 |
| Source Interval | 15 |
| State | MA |
| Symbol | EYPT |
| Target High Price | 68.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 25.90909 |
| Target Median Price | 20.0 |
| Total Cash | 180,472,000 |
| Total Cash Per Share | 2.093 |
| Total Debt | 22,367,000 |
| Total Revenue | 2,788,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.75 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.03245 |
| Two Hundred Day Average Change | -9.04245 |
| Two Hundred Day Average Change Percent | -0.7515053 |
| Type Disp | Equity |
| Volume | 1,036,203 |
| Website | https://eyepoint.bio |
| Zip | 2,472 |